Clozel’s Actelion R&D spinout gets a name; GSK’s new CEO won’t make as much as her predecessor
→ Jean-Paul Clozel has a name for his biotech spinout. Once J&J’s $30 billion deal to acquire Actelion goes through, the R&D side of the business will launch under the name Idorsia. When the deal was originally announced, Clozel had pencilled in NewCo for his next venture.
→ Aurinia $AUPH took advantage of a rising share price to round up $150 million in a new offering. But the stock took a beating Tuesday after the biotech decided to offer the shares at a deep discount.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.